Navigation Links
Chinese State Food and Drug Administration Approves Company Facility for Producing Solid Dosage Perindopril
Date:1/25/2010

NANTONG, China, Jan. 25 /PRNewswire-Asia-FirstCall/ -- Sinobiopharma, Inc. ("Sinobiopharma" or, the "Company") (OTC Bulletin Board: SNBP) is pleased to announce that its production facility for solid dosage Perindopril has passed the required Chinese State Food and Drug Administration (SFDA) inspection and is now approved for production and marketing.

Sinobiopharma had received SFDA approval for its formulation of Perindopril, the first version of the drug to be developed in China, in April 2009.  SFDA regulations require that drug makers conduct large-scale production of at least three batches of a newly approved drug in a Good Manufacturing Practice (GMP) certified production facility. SFDA officials inspect the production process, the application of GMP standards, and conducted a full test of randomly picked samples of the drug. Sinobiopharma successfully met all the requirements and now has received approval to distribute the drug throughout China.

The Company believes its formulation of Perindopril is the latest generation worldwide of the product, which is part of a class of medications known as angiotensin-converting enzyme (ACE) inhibitors. These medications are used alone or in combination with other medications to treat high blood pressure.  Perindopril allows blood to flow more smoothly by preventing the production of certain natural chemicals that constrict blood vessels.  Every year, US$3.7 billion is spent on the treatment of hypertension in China.  Sinibiopharma's Perindopril will be marketed under the trade name YiTai in China.  

"We believe that YiTai is a first-to-market drug in China and therefore enjoys the benefit of having a government sanctioned price premium as well as certain exclusive marketing rights to hospitals," said Dr. Lequn Lee Huang, CEO of the Company. "The market for anti-hypertensives in China is huge, but highly fragmented. Sinobiopharma's YiTai is well positioned to capture substantial market share quickly."

About Sinobiopharma

Sinobiopharma, Inc. is a fully integrated and highly innovative specialty biopharmaceutical company engaged in the research and development, manufacture and marketing of biopharmaceutical products in China, one of the world's fastest growing pharmaceutical markets. Known as Dong Ying (Jiangsu) Pharmaceutical Co., Ltd. in China, the Company's current therapeutic focus is on anesthesia-assisted agents and cardiovascular drugs.

FORWARD LOOKING STATEMENTS

This news release may include "forward-looking statements" regarding Sinobiopharma, Inc., and its subsidiaries, business and project plans. Such forward looking statements are within the meaning of Section 27A of the Securities Act of 1933, as amended, and section 21E of the United States Securities and Exchange Act of 1934, as amended, and are intended to be covered by the safe harbor created by such sections. Where Sinobiopharma, Inc. expresses or implies an expectation or belief as to future events or results, such expectation or belief is believed to have a reasonable basis. However, forward-looking statements are subject to risks, uncertainties and other factors, which could cause actual results to differ materially from future results expressed, projected or implied by such forward-looking statements. Sinobiopharma, Inc. does not undertake any obligation to update any forward looking statement, except as required under applicable law.

SOURCE Sinobiopharma, Inc.


'/>"/>
SOURCE Sinobiopharma, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Tianyin Pharmaceutical Co., Inc. Receives Chinese SFDA Approval for Ofloxacin and Fleroxacin
2. Sinovac Obtains Fifth H1N1 Vaccine Order from Chinese Central Government
3. Olympic Winner Xiong Ni, Spokesperson for Endoscopic Medicine -- Chinese Minimally Invasive Advanced Technology Top in the World
4. GeoInvesting.com Offers Insight Into Two Growing Chinese Pharmaceutical Firms
5. Chinese-American Women & Korean-American Women at Highest Risk for Developing Diabetes During Pregnancy
6. Tianyin Pharmaceutical Co., Inc. Receives Chinese SFDA New Product Approvals for 2 Generic Products
7. Sinovac Obtains Fourth H1N1 Vaccine Order from Chinese Central Government
8. Reportlinker Adds Brazil, Russian, Indian and Chinese Markets for Endoscopic Devices 2009 (4 Countries)
9. Reportlinker Adds Chinese Markets for Bladder Cancer Treatment Drugs
10. Reportlinker Adds Chinese Markets for Respiratory Drugs
11. NeoStem Acquires China Biopharmaceuticals Holdings, Inc.; Obtains Controlling Interest in Profitable Leading Chinese Pharmaceutical Company
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/24/2016)... , Belgium , June ... MKT: VNRX), today announced the appointment of Dr. ... of Directors as a Non-Executive Director, effective June ... Company,s Audit, Compensation and Nominations and Governance Committees.  ... Dr. Futcher will provide independent expertise and strategic ...
(Date:6/23/2016)... Research and Markets has announced the addition ... Chemical (Sugar, Petrochemical, Glycerin), Inorganic Chemical), Functionality (Filler, Binder, ... Forecast to 2021" report to their offering. ... excipients market is projected to reach USD 8.1 Billion ... forecast period 2016 to 2021. The ...
(Date:6/23/2016)... -- Research and Markets has announced the addition ... to their offering. The ... commercial environment for MedImmune to enter. The US ageing population ... to drive considerable growth for effective anti-influenza medications. The introduction ... considerably, but development is still in its infancy. ...
Breaking Medicine Technology:
(Date:6/26/2016)... Lake Orion, Clarkston, Michigan (PRWEB) , ... June ... ... direction with respect to fertility once they have been diagnosed with endometriosis. These ... tolerable intercourse but they also require a comprehensive approach that can help for ...
(Date:6/25/2016)... TX (PRWEB) , ... June 25, 2016 , ... ... the United States, named Dr. Sesan Ogunleye, as the Medical Director of its new ... the facility Medical Director of our new Mesquite location,” said Dr. James M. Muzzarelli, ...
(Date:6/24/2016)... ... , ... A recent article published June 14 on E Online ... on to state that individuals are now more comfortable seeking to undergo not only ... calf and cheek reduction. The Los Angeles area medical group, Beverly Hills Physicians (BHP) ...
(Date:6/24/2016)... (PRWEB) , ... June 24, 2016 , ... Global law ... magazine’s 2016 Legal Elite. The attorneys chosen by their peers for this recognition are ... , Seven Greenberg Traurig Shareholders received special honors as members of this year’s Legal ...
(Date:6/24/2016)... ... June 24, 2016 , ... ... Clinical Decision Making in Emergency Medicine conference in Ponte Vedra Beach, FL. The ... published in Emergency Medicine Practice and Pediatric Emergency Medicine Practice. , ...
Breaking Medicine News(10 mins):